Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
09 Gennaio 2023 - 1:00PM
Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a
clinical-stage biopharmaceutical company focused on developing
next-generation tumor infiltrating lymphocyte, or TIL, therapies
for the treatment of patients with cancer, today announced the
resumption of its Phase 1 clinical trial of ITIL-306 for the
treatment of non-small cell lung cancer (NSCLC), ovarian cancer,
and renal cell carcinoma (RCC).
With the resumption of the ITIL-306 Phase 1 study, the Company
expects to release initial safety, translational, and efficacy data
from dose escalation cohorts at a medical conference in 2023. The
trial was resumed after the implementation of additional quality
safeguards designed to further protect the manufacturing process
from potential contaminants.
Following its recent reprioritization of clinical programs and
corporate restructuring, Instil expects its cash runway to extend
into 2025, excluding the potential financing or other monetization
of its Tarzana manufacturing site. Instil intends to provide
further updates on its pre-clinical pipeline in 2023, including the
potential to nominate additional CoStAR candidates and novel TIL
technologies for clinical development.
About Instil BioInstil Bio, Inc. (Nasdaq: TIL)
is a clinical-stage biopharmaceutical company focused on developing
next-generation TIL therapies for the treatment of patients with
cancer. The Company has assembled an accomplished management team
with a successful track record in the research, development,
manufacture, and commercialization of cell therapies. Instil is
advancing its lead CoStAR-TIL product candidate, ITIL-306, a
next-generation, genetically-engineered TIL therapy for multiple
solid tumors. For more information visit www.instilbio.com and
LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“anticipates,” “believes,” “expects,” “future,” “intends,”
“potential,” “projects,” and “will” or similar expressions are
intended to identify forward-looking statements. Forward-looking
statements include statements concerning or implying our pipeline
of potential therapies and the development thereof, including
potential nomination of additional CoStAR candidates and novel TIL
technologies for clinical development and the timing thereof, our
plans regarding enrollment in our ITIL-306 clinical trial and
expectations concerning the availability of initial clinical data
from such study and the timing thereof, our cash runway, the
anticipated financing or other monetization of our Tarzana, CA
manufacturing facility and other statements that are not historical
fact. Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements,
including risks and uncertainties associated with the costly and
time-consuming cell therapy product development process and the
uncertainty of clinical success, including risks related to failure
or delays in successfully initiating, enrolling, reporting data
from or completing clinical studies, as well as the risks that
results obtained in clinical trials to date may not be indicative
of results obtained in ongoing or future trials and that our
product candidates may otherwise not be effective treatments in
their planned indications; the risk that the implementation of
additional quality safeguards to our manufacturing processes may
not be effective; the ongoing COVID-19 pandemic, which could
materially and adversely affect our business and operations,
including our ability to timely initiate, enroll and complete our
ongoing and future clinical trials; the time-consuming and
uncertain regulatory approval process; risks inherent in
manufacturing and testing of cell therapy products; the sufficiency
of our cash resources; our ability to achieve the expected benefits
of our corporate reorganization; and other risks and uncertainties
affecting Instil and its development programs, including those
discussed in the section titled “Risk Factors” in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2022
available on the SEC’s website at www.sec.gov. Additional
information will be made available in other filings that we make
from time to time with the SEC. Such risks may be amplified by the
impacts of the COVID-19 pandemic. Accordingly, these
forward-looking statements do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on
these forward-looking statements. These forward-looking statements
speak only as of the date hereof, and we disclaim any obligation to
update these statements except as may be required by law.
Contacts:Media Contact:1-833-446-7845 Ext.
1009mediarelations@instilbio.com
Janhavi MohiteStern Investor
Relations1-212-362-1200janhavi.mohite@sternir.com
Grafico Azioni Instill Bio (NASDAQ:TIL)
Storico
Da Mag 2024 a Mag 2024
Grafico Azioni Instill Bio (NASDAQ:TIL)
Storico
Da Mag 2023 a Mag 2024